EMSOS 2009
13 – 16 MAY 2009
STUTTGART, GERMANY
MAIN PROGRAM AND BOOK OF ABSTRACTS

CONFERENCE
22nd ANNUAL MEETING OF THE
EUROPEAN MUSCULO-SKELETAL
ONCOLOGY SOCIETY (EMSOS)

TRAINING DAY
1st Stuttgart Training Day on
Bone Tumors in Children and
Adolescents

SYMPOSIUM
10th Symposium of the EMSOS
Nurses and Allied Health Pro-
fessionals Group

INDEX:
03 Welcome
07 Program overview
11 Program: Training Day on Bone
Tumors in Children and
Adolescents
15 Program: EMSOS Nurses &
Allied Professionals Group
19 EMSOS Program in detail
38 Program GPOH Research Forum
43 Abstracts
299 Index of authors

NAME:

implantcast GmbH
Lüneburger Schanze 26
D-21614 Buxtehude
phone: +49 4161 744-0
fax: +49 4161 744-200
e-mail: info@implantcast.de
www.implantcast.de
ARIAD Pharmaceuticals, Inc. and MSD are pleased to announce SUCCEED – a multinational, randomized, Phase 3, double-blind, placebo-controlled trial to determine the efficacy and safety of oral ridaforolimus (formerly deforolimus) when administered as maintenance therapy to patients with metastatic soft-tissue or bone sarcomas who have had a favorable outcome to chemotherapy.

To learn more about the SUCCEED trial, or to find a trial site nearby, please call the international number 1-617-621-2302 or visit www.ClinicalTrials.gov (NCT00538239).

ARIAD Pharmaceuticals, Inc. and MSD have a global collaboration to jointly investigate ridaforolimus for the treatment of cancer.